Top

Medical Oncology

Published in:

01-12-2012 | Letter to the Editor

Vitiligo-like hypopigmentation and metastatic melanoma of unknown primary site: friends or foes?

Authors: Julio Cesar Salas-Alanis, Roger Gonzalez, Giulio Fortuna

Published in: Medical Oncology | Issue 4/2012

Excerpt

To the Editor, …

Savoia P, Fava P, Osella-Abate S, et al. Melanoma of unknown primary site: a 33-year experience at the Turin Melanoma Centre. Melanoma Res. 2010;20:227–32.PubMed

Quaglino P, Marenco F, Osella-Abate S, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol. 2010;21:409–14.PubMedCrossRef

Pfeil AF, Leiter U, Buettner PG, et al. Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009. Melanoma Res. 2011;21:228–34.PubMedCrossRef

Schlagenhauff B, Stroebel W, Ellwanger U, et al. Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. Cancer. 1997;80:60–5.PubMedCrossRef

Savoia P, Fava P, Nardò T, Osella-Abate S, Quaglino P, Bernengo MG. Skin metastases of malignant melanoma: a clinical and prognostic survey. Melanoma Res. 2009;19:321–6.PubMedCrossRef

Kamposioras K, Pentheroudakis G, Pectasides D, Pavlidis N. Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol. 2011;78:112–26.PubMedCrossRef

Cho EA, Lee MA, Kang H, Lee SD, Kim HO, Park YM. Vitiligo-like depigmentation associated with metastatic melanoma of an unknown origin. Ann Dermatol. 2009;21:178–81.PubMedCrossRef

Title: Vitiligo-like hypopigmentation and metastatic melanoma of unknown primary site: friends or foes?
Authors: Julio Cesar Salas-Alanis
Roger Gonzalez
Giulio Fortuna
Publication date: 01-12-2012
Publisher: Springer US
Published in: Medical Oncology / Issue 4/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-011-0146-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Vitiligo-like hypopigmentation and metastatic melanoma of unknown primary site: friends or foes?

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2012

Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy

P-cadherin expression and basal-like subtype in breast cancers

High expression of CXCR2 is associated with tumorigenesis, progression, and prognosis of laryngeal squamous cell carcinoma

Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab

Overexpression of the HIF hydroxylase PHD3 is a favorable prognosticator for gastric cancer

Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page